ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPHNewsfile Corp • 04/20/22
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 04/19/22
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus NephritisBusiness Wire • 04/19/22
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)Business Wire • 04/19/22
ALERT: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPHPRNewsWire • 04/18/22
EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AUPHBusiness Wire • 04/18/22
SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Aurinia Pharmaceuticals Investors (AUPH) and Encourages Investors With Significant Losses To Contact the FirmNewsfile Corp • 04/18/22
AURINIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/16/22
AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPHBusiness Wire • 04/05/22
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical MeetingsBusiness Wire • 04/04/22
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPHPRNewsWire • 03/27/22
AUPH Equity Alert: ROSEN, Top Ranked Investor Counsel, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPHNewsfile Corp • 03/24/22
AUPH INVESTOR NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPHNewsfile Corp • 03/21/22
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/16/22
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPHPRNewsWire • 03/15/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/15/22
AUPH Investor Alert: ROSEN, A Top Ranked Law Firm, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - AUPHNewsfile Corp • 03/13/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurinia Pharmaceuticals Inc. - AUPHPRNewsWire • 03/10/22
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPHBusiness Wire • 03/07/22
Despite Market Reaction, Aurinia Pharmaceuticals Is On Track And Ahead Of ScheduleSeeking Alpha • 03/07/22
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/28/22
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company UpdatesBusiness Wire • 02/28/22
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/21/22
